Sonja Willems – Managing Director, Janssen Benelux
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
Address: Avenue Ariane 16 1200 Brussels Belgium
Tel: +32 (0)2 773 33 11
Web: http://www.boehringer-ingelheim.be/
The Boehringer Ingelheim group
Our group, established in Ingelheim (Germany), has 137 subsidiaries across 47 countries and approximately 41,500 employees, of which nearly 5,000 are active in research and development.
Since its foundation in 1885, the group is still wholly owned by the founding family and focused on researching, developing and producing and marketing of new products with high added value for medical use, also in veterinary medicine.
In Belgium and Luxembourg Boehringer Ingelheim employs over 250 staff working in the sales and distribution of pharmaceutical products for humans and animals and in clinical research.
With research as our main growth engine, developing our laboratories breakthrough medicines for use in diverse areas such as pneumology, cardiology, rheumatology, neurology, virology and oncology. Boehringer Ingelheim also develops products for self-medication and phyto-pharmaceuticals, and a series products for veterinary use. Our activities extend also to the chemical and biopharmaceutical manufacturing. Our main activity in Belgium includes the sale and distribution of pharmaceutical products for humans and animals, as well as clinical research.
Janssen in Belgium was founded in 1953 by Dr Paul Janssen, with only one thing in mind: saving people’s lives through the development of better medicines. In 1961, the company…
Professor Sylvie Rottey, president of the Belgian Society of Medical Oncology (BSMO) outlines the state of cancer care in Belgium, the country’s positioning in clinical trials for medical oncology, and…
Erik Present is president of Healixia, a newly formed association for medical professionals in Belgium. Present introduces the mission and purpose of Healixia, the work it is currently undertaking in…
Sabena Solomon, general manager of GSK Benelux, speaks about her first impressions of the Belgium market, having come from GSK Finland, and her initial priorities for leading the affiliate. Solomon…
Karel Van De Sompel, country manager of Pfizer in Belgium and Luxembourg and chairman of Pharma.be, highlights the key changes he sees in today’s pharma market which revolve around the…
Professor Stéphane De Wit, head of the Department of Infectious Diseases at St Pierre University Hospital outlines Belgium’s approach to tackling HIV treatment, how academia-industry collaboration is progressing in the…
In 2020 PharmaBoardroom sat down with several key stakeholders in Belgian pharma to discuss company strategy, the Belgian healthcare landscape at large, and the country’s role within the wider European…
Francis Arickx, country coordinator of Belgium for the Beneluxa Initiative, introduces the project and its mission to help shape a unified healthcare policy approach between its member countries through activities…
Ian Wilders of Spain-headquartered micro-immunotherapy specialist Labo’Life discusses the strategic importance of Belgium to the company as the country in which micro-immunotherapy was discovered and where regulation conducive to the…
Luc Van Gorp of the Christian Mutuality Health Insurance Fund, Belgium’s largest health insurance fund, explains the organisation’s role within the Belgian healthcare system, how increased consolidation in recent years…
Dirk Reyn of Flanders.bio highlights what the Flanders region has to offer the life sciences and biotech industries in terms of research infrastructure, funding opportunities, and inter-industry collaboration. In…
Anne-Laure Dreno, country president of AstraZeneca in Belgium, elaborates on the significant position Belgium and the local affiliate have for the group as a frontrunner in innovative areas such as…
See our Cookie Privacy Policy Here
